|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 10,039,766
United States Patent 10,039,766, titled "Methods of treating conditions with substituted pyrimidine derivatives," issued on August 7, 2018, to The Board of Trustees of the Leland Stanford Junior University. The patent claims methods for treating various medical conditions using specific substituted pyrimidine compounds. The patent's claims focus on the therapeutic application of these compounds, primarily related to inhibiting Janus kinases (JAKs). The landscape surrounding JAK inhibitors is highly competitive, with multiple companies holding significant patent portfolios covering distinct chemical entities and their therapeutic uses. Understanding the precise scope of this patent is critical for assessing freedom to operate and identifying potential licensing or infringement risks.
What are the Core Therapeutic Claims of Patent 10,039,766?
The patent claims methods for treating conditions characterized by the abnormal activity of Janus kinases (JAKs), particularly JAK1, JAK2, JAK3, and TYK2. The asserted therapeutic uses include, but are not limited to, inflammatory diseases, autoimmune diseases, myeloproliferative disorders, and certain types of cancer.
- Claim 1: This independent claim describes a method of treating a patient with a condition characterized by abnormal JAK activity. The method involves administering to the patient a therapeutically effective amount of a compound of Formula I. Formula I encompasses a broad range of substituted pyrimidine derivatives.
- Formula I Structure: The compound of Formula I is defined by specific substituents at various positions of a pyrimidine core. Key structural elements include:
- A pyrimidine ring.
- Substituents at positions 2, 4, 5, and 6 of the pyrimidine ring.
- Specific heterocyclic or carbocyclic groups attached to these positions.
- Detailed definitions for the various R groups (e.g., R1, R2, R3, R4) including hydrogen, alkyl, aryl, heteroaryl, amino, alkoxy, and halogen groups, and their further substitutions.
- Specific Conditions: The patent explicitly lists several conditions to which these methods apply, including but not limited to:
- Rheumatoid arthritis
- Psoriatic arthritis
- Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
- Lupus
- Myelofibrosis
- Polycythemia vera
- Essential thrombocythemia
- Cancer, including hematological malignancies and solid tumors.
- JAK Inhibition: The method is predicated on the compound's ability to inhibit one or more JAK enzymes. The patent does not narrowly define the level of inhibition required but rather links the therapeutic effect to the inhibition of JAK activity.
- Dependent Claims: Numerous dependent claims further refine the scope by specifying particular structural variations within Formula I, preferred JAK targets (e.g., JAK1, JAK2), and specific disease indications. For example, some dependent claims may specify a particular R group or a subset of the listed diseases.
What are the Key Structural Definitions and Embodiments within the Patent?
The patent defines a chemical space of substituted pyrimidine derivatives through detailed Markush structures and specific examples. The core is a pyrimidine ring, with varying functional groups attached at positions 2, 4, 5, and 6.
- Pyrimidine Core: The central structural motif is a pyrimidine ring, a six-membered heterocyclic aromatic organic compound containing two nitrogen atoms at positions 1 and 3.
- Formula I:
- Position 2: Typically substituted with an amino group, which can be further derivatized.
- Position 4: Often bears a substituted aryl or heteroaryl ring.
- Position 5: Can be substituted with various groups, including halogens or carbon-based chains.
- Position 6: May be unsubstituted or bear a smaller substituent.
- R Groups: The patent extensively defines R groups, which are crucial for defining the scope of the claimed compounds. These R groups can include:
- Hydrogen
- Alkyl groups (e.g., methyl, ethyl)
- Haloalkyl groups (e.g., trifluoromethyl)
- Cycloalkyl groups
- Aryl groups (e.g., phenyl)
- Heteroaryl groups (e.g., pyridyl, pyrazolyl)
- Amino groups (-NR'R'')
- Alkoxy groups (-OR')
- Halogen atoms (e.g., F, Cl, Br)
- Carboxylic acids, esters, and amides.
- Specific Examples: The patent includes numerous specific compounds prepared and characterized. These examples serve to illustrate the types of compounds covered by the broader Markush claims. These examples typically provide detailed synthetic procedures and characterization data (e.g., NMR, Mass Spectrometry). A detailed examination of these examples is critical for understanding potential off-patent or unpatentable structures.
- Stereochemistry: While not a primary focus for all compounds, if chiral centers exist due to specific substituents, the patent may claim racemic mixtures or specific enantiomers.
- Salt Forms and Polymorphs: The claims are generally directed to the compounds themselves, but prosecution history and related patents might address specific salt forms, solvates, or polymorphs if they demonstrate unexpected advantageous properties.
What is the Patent Landscape for JAK Inhibitors and Where Does 10,039,766 Fit?
The JAK inhibitor market is characterized by extensive patenting activity from major pharmaceutical companies. Patent 10,039,766 is one of many patents related to JAK inhibition, focusing on a specific class of substituted pyrimidine derivatives.
- Key Players and Patents:
- Incyte Corporation: Holds foundational patents for ruxolitinib (Jakafi/Jakavi) and other JAK inhibitors. Their patent portfolio covers specific chemical structures and uses for myeloproliferative neoplasms. For example, US Patent 7,598,257 is a key patent for ruxolitinib.
- Pfizer Inc.: Developed tofacitinib (Xeljanz). Their patents, such as US Patent 7,301,021, cover pyrazolopyrimidine JAK inhibitors.
- AbbVie Inc.: Developed upadacitinib (Rinvoq) and filgotinib (Jyseleca). Their portfolio includes patents on pyrrolo[2,3-d]pyrimidine derivatives.
- Eli Lilly and Company: Developed baricitinib (Olumiant). Patents cover azaindole compounds.
- Concert Pharmaceuticals: Developing deuterated forms of existing JAK inhibitors.
- Patent Strategies: Companies employ several strategies:
- Composition of Matter Patents: These are the strongest, claiming the novel chemical entities.
- Method of Use Patents: Claiming new therapeutic applications for known compounds or specific methods of treatment.
- Process Patents: Claiming novel synthetic routes.
- Formulation Patents: Claiming specific dosage forms or delivery systems.
- Polymorph Patents: Claiming specific crystalline forms of active pharmaceutical ingredients.
- Position of Patent 10,039,766: This patent falls into the "Method of Use" category, focusing on treating conditions via JAK inhibition using a defined structural class of pyrimidine derivatives. It does not appear to claim novel chemical entities as its primary focus, but rather the application of these known or derivable pyrimidine structures.
- Overlap and Differentiation: The patent's broad definition of Formula I and the associated R groups may overlap with existing patents if similar pyrimidine scaffolds are claimed as compositions of matter. The differentiation lies in the specific therapeutic methods and the detailed structural scope of the claimed compounds.
- Freedom to Operate (FTO): Companies developing JAK inhibitors must conduct thorough FTO analyses to ensure their proprietary compounds and therapeutic approaches do not infringe on existing patents. This includes analyzing the structural similarity of their compounds to those claimed in patents like 10,039,766 and evaluating whether their intended therapeutic indications are covered.
- Prior Art: The patent's validity and enforceability will depend on the prior art that existed before its filing date. Significant prior art disclosing similar pyrimidine structures or their JAK inhibitory activity could limit its scope or render it invalid.
What are the Implications for Research and Development (R&D)?
Patent 10,039,766 has several implications for R&D activities in the JAK inhibitor space. Understanding its claims is crucial for navigating the competitive landscape and identifying areas for innovation.
- Target Identification: The patent reinforces the therapeutic relevance of JAK inhibition for a wide array of inflammatory, autoimmune, and oncological conditions. This can guide R&D efforts towards exploring novel targets within the JAK signaling pathway or identifying new disease indications amenable to JAK inhibition.
- Chemical Space Exploration: While the patent claims a specific class of substituted pyrimidines, its existence highlights the ongoing interest in this chemical scaffold for drug discovery. Researchers may explore:
- Variations on the Pyrimidine Core: Developing novel heterocyclic cores that are structurally distinct but achieve similar therapeutic effects.
- New Substituent Combinations: Investigating novel R group combinations within the pyrimidine structure that may offer improved efficacy, selectivity, or pharmacokinetic profiles.
- Selectivity for JAK Isoforms: Developing inhibitors with enhanced selectivity for specific JAK isoforms (e.g., JAK1-selective inhibitors) to minimize off-target effects and improve the therapeutic index.
- Freedom to Operate (FTO) for New Compounds: Any R&D team designing new pyrimidine-based JAK inhibitors must carefully assess whether their intended chemical structures fall within the scope of Formula I as defined in this patent and its dependent claims. This requires detailed chemical structure comparison and legal interpretation of claim language.
- Post-Grant Review and Litigation Risk: The patent, being issued, is subject to potential post-grant challenges (e.g., inter partes review) or litigation if companies believe it is being infringed upon. The broad nature of some claims could make them attractive targets for such challenges.
- Licensing Opportunities: If a company has developed a compound that falls outside the scope of this patent but exhibits therapeutic potential, it might represent a licensing opportunity if the patent holder wishes to broaden their portfolio or depopulate the field. Conversely, if a company's pipeline compounds are structurally close to the patented class, securing a license might be necessary.
- Repurposing Existing Compounds: The patent might also inform efforts to repurpose existing pyrimidine-based compounds that have shown JAK inhibitory activity, provided their structural elements align with Formula I.
What are the Strategic and Investment Considerations?
For businesses operating in the pharmaceutical or biotechnology sectors, patent 10,039,766 presents several strategic and investment considerations related to R&D, portfolio management, and competitive positioning.
- Competitive Intelligence: This patent is a key piece of intelligence in understanding the R&D and patent strategies of academic institutions and their potential commercialization partners. It signals an area where innovation has been pursued and patented.
- Due Diligence for M&A and Licensing: In mergers, acquisitions, or licensing deals involving companies with JAK inhibitor programs, this patent must be a core element of the intellectual property due diligence. Its scope and remaining lifespan will impact the value and risk associated with the target asset.
- Investment in JAK Inhibitor Therapeutics: Investors evaluating companies in the inflammation, autoimmune, or oncology space should consider the patent landscape, including patents like 10,039,766. The existence of such patents influences the exclusivity period and potential market penetration of new entrants.
- Portfolio Diversification: Companies with existing JAK inhibitor portfolios should analyze their own patents against 10,039,766 to identify any potential overlaps, potential infringement risks, or opportunities for defensive patenting around novel pyrimidine derivatives.
- Market Entry Strategy: For new entrants into the JAK inhibitor market, a comprehensive understanding of this patent and its claims is essential for designing a market entry strategy that minimizes legal challenges and maximizes intellectual property protection. This includes identifying "white space" in the patent landscape.
- Patent Expiration Analysis: The patent's issue date is August 7, 2018. Assuming standard patent term extension provisions and no additional extensions, the patent is expected to expire approximately 20 years from its filing date. A precise calculation would require knowledge of the original filing date and any terminal disclaimers or extensions. This expiration date is critical for anticipating the entry of generic or biosimilar competition.
Key Takeaways
United States Patent 10,039,766 claims methods for treating conditions by administering substituted pyrimidine derivatives that inhibit Janus kinases (JAKs). The patent defines a broad scope of chemical structures within Formula I and lists numerous therapeutic indications, including inflammatory, autoimmune, and myeloproliferative disorders. The patent's claims focus on the therapeutic application rather than novel chemical entities, placing it within a highly competitive JAK inhibitor landscape dominated by major pharmaceutical companies. R&D efforts must navigate this patent's scope for freedom to operate and identify areas for innovation. Strategic and investment decisions should incorporate this patent's implications for competitive positioning, M&A, and market entry.
FAQs
-
What is the primary legal protection offered by Patent 10,039,766?
The patent provides legal protection for methods of treating specific medical conditions using a defined class of substituted pyrimidine derivatives that inhibit Janus kinases. It protects the use of these compounds in therapy, not necessarily the compounds themselves as novel chemical entities if they were previously known.
-
Does Patent 10,039,766 claim specific pharmaceutical drugs?
The patent claims methods of treatment using compounds falling within a broad chemical structure (Formula I). While specific compounds are exemplified, the claims are generally method-of-use claims. It is possible that some of the exemplified compounds correspond to, or are closely related to, existing or investigational drugs, but the patent's strength lies in the method of use for treating specific diseases via JAK inhibition with this chemical class.
-
How long is Patent 10,039,766 expected to be in force?
As a U.S. utility patent, it is generally granted for a term of 20 years from the filing date, subject to the payment of maintenance fees. Without the original filing date, a precise expiration cannot be stated, but it is 20 years from the earliest U.S. non-provisional filing date. Patent term adjustments or extensions could alter this date.
-
What does "abnormal JAK activity" mean in the context of this patent?
"Abnormal JAK activity" refers to the overactivity or dysregulation of Janus kinase enzymes (JAK1, JAK2, JAK3, TYK2) which is implicated in the pathogenesis of various inflammatory, autoimmune, and proliferative diseases. The patent claims therapies that mitigate the consequences of this abnormal activity through inhibition of these enzymes.
-
Can a company develop a pyrimidine-based JAK inhibitor if Patent 10,039,766 exists?
A company can develop a pyrimidine-based JAK inhibitor, but it must conduct a thorough freedom-to-operate analysis. If their proposed compound and method of use fall within the scope of the claims of Patent 10,039,766, they may require a license from the patent holder (The Board of Trustees of the Leland Stanford Junior University) to avoid infringement.
Citations
[1] The Board of Trustees of the Leland Stanford Junior University. (2018). Methods of treating conditions with substituted pyrimidine derivatives (U.S. Patent No. 10,039,766). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
